Reported Friday, Citius Pharmaceuticals FY24 EPS $(5.97) Down From $(5.57) YoY; Cash $3.3M
Reported Friday, Citius Pharmaceuticals FY24 EPS $(5.97) Down From $(5.57) YoY; Cash $3.3M
Net loss was $39.4 million, or ($5.97) per share for the year ended September 30, 2024, compared to a net loss of $32.5 million, or ($5.57) per share for the year ended September 30, 2023, as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense.
截至2024年9月30日，淨虧損爲3940萬美元，摺合每股（$5.97），相比於截至2023年9月30日的淨虧損3250萬美元，摺合每股（$5.57），已根據反向股票拆分進行了調整。淨虧損的增加反映了運營費用的增加爲530萬美元，其他收入減少160萬美元的影響。運營費用的增加是由於基於股票的補償和一般及管理費用的增加，而研發費用的減少則抵消了一部分影響。
As of September 30, 2024, the Company had $3.3 million in cash and cash equivalents.
截至2024年9月30日，公司擁有現金及現金等價物330萬美元。
